IP Library › Granted Patent US 11,376,218
Granted Patent B2
US 11,376,218 · App. 15/567,878 · Granted Jul 5, 2022

Method for preparing transmembrane pH-gradient vesicles

Inventors: Jean-Christophe Leroux (Zurich, CH); Vincent Forster (Zurich, CH); Valentina Agostoni (Zurich, CH)
Assignee: Versantis AG
A61K9/1277A61K9/127
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,376,218
App. No.
15/567,878
Granted
Jul 5, 2022
Kind
B2
Abstract

The invention relates to a method for preparing transmembrane pH-gradient vesicles. This method includes the following steps: a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l. The matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers, b) transferring the vesicles into a basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles and c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a neutralizing solution to obtain transmembrane pH-gradient vesicles suspended in a suspension buffer, which differs from the basic or acidic buffer in pH value.

Claims (19)

1. A method for preparing transmembrane pH-gradient vesicles, comprising the steps of:

a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l and a pH in the range of 6.0 to 7.5, wherein the matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers, sterilizing the vesicles, and, optionally, storing the sterilized vesicles,

b) mixing the sterilized vesicles with a sterile basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles, wherein the basic or acidic buffer is added in an amount sufficient to cause temporary destabilization of the vesicles in step b), and

c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a sterile neutralizing solution to obtain sterile transmembrane pH-gradient vesicles suspended in a sterile suspension buffer, wherein the suspension buffer differs from the basic or acidic buffer in pH value, and wherein the neutralizing solution does not destabilize the vesicles in step c).

2. The method according to claim 1 , wherein the vesicles are stored for a first period of time prior to carrying out step b).

3. The method according to claim 1 , wherein step b) is carried out at a temperature that is below a phase transition temperature of the matrix substance.

4. The method according to claim 1 , wherein step b) is carried out at a temperature of not more than 35° C.

5. The method according to claim 1 , wherein the osmolarity of the basic or acidic buffer is at least 250 mOsm/l.

6. The method according to claim 1 , wherein the mixture of the aqueous medium and the basic or acidic buffer in which the buffer-filled vesicles are suspended at the end of step b) has an osmolarity of at least 200 mOsm/l.

7. The method according to claim 1 , wherein the neutralizing solution has an osmolarity of between 250 mOsm/l and 550 mOsm/l.

8. The method according to claim 1 , wherein the neutralizing solution of step c) further comprises at least one substance chosen from the group consisting of glycerol, xylitol, TRIS, glucose, magnesium salts, sodium hydroxide, sodium salts and calcium salts.

9. The method according to claim 1 , wherein the pH value of the suspension buffer containing the transmembrane pH-gradient vesicles is in a range of 5.5 to 8.5.

10. The method according to claim 1 , wherein the aqueous medium is chosen from the group consisting of water, aqueous solutions of organic salts, aqueous solutions of inorganic salts, aqueous solutions of organic substances, and combinations thereof.

11. The method according to claim 1 , wherein the matrix substance is chosen from the group consisting of dipalmitoylphosphatidylcholine, 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[methoxy(PEG)-2000], cholesterol and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, and combinations thereof.

12. The method according to claim 1 , wherein the vesicles prepared in step a) are sterilized by autoclaving.

13. The method according to claim 1 , wherein the aqueous medium of step a) has an osmolarity that is equal to or less than 50 mOsm/L.

14. A method for preparing sterile transmembrane pH-gradient vesicles, comprising the steps of:

a) mixing (i) a sterilized aqueous medium comprising sterilized vesicles filled with the aqueous medium, the vesicles being made from at least one matrix substance chosen from amphiphilic lipids, the aqueous medium having an osmolarity of not more than 200 mOsm/l and a pH in the range of 6.0 to 7.5, with (ii) a sterile basic buffer having a pH of at least 8.5 or a sterile acidic buffer having a pH of 5.5 or less, the sterile basic or acidic buffer having an osmolarity at least 400 mOsm/l higher than the aqueous medium, to apply an osmotic shock to the vesicles and to obtain basic or acidic buffer-filled vesicles, wherein the basic or acidic buffer is in an amount sufficient to cause temporary destabilization of the vesicles in step a); and

b) diluting the mixture of step a) by adding a sterile neutralizing solution to obtain sterile transmembrane pH-gradient vesicles suspended in a sterile suspension buffer, wherein the suspension buffer differs from the basic or acidic buffer of step a) in pH value, and wherein the neutralizing solution does not destabilize the vesicles in step b).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2026
From: VERSANTIS AG
To: GENFIT
Reel/Frame 073455/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2018
From: LEROUX, JEAN-CHRISTOPHE; FORSTER, VINCENT; AGOSTONI, VALENTINA
To: ETH ZURICH
Reel/Frame 044700/0431 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2018
From: ETH ZURICH
To: VERSANTIS AG
Reel/Frame 044700/0440 →
Priority Claims (1)
EP 15166247 · May 4, 2015 · regional
Continuity (1)
Related Publication 20180104189A1 · Apr 19, 2018
Cited By (1)
US 12,427,112